17 studies found for:    richardson | myeloma
Show Display Options
Rank Status Study
1 Recruiting Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone;   Procedure: Autologous Stem Cell Transplant
2 Active, not recruiting Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
3 Completed Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
Conditions: Multiple Myeloma;   Multiple Myeloma in Relapse
Interventions: Drug: Perifosine;   Drug: Bortezomib;   Drug: Dexamethasone
4 Terminated Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Perifosine;   Drug: Perifosine Placebo;   Drug: Bortezomib;   Drug: Dexamethasone
5 Active, not recruiting Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Part 1 (Dose Escalation): Daratumumab;   Drug: Part 2 (Dose Expansion): Daratumumab;   Drug: Lenalidomide;   Drug: Dexamethasone
6 Active, not recruiting
Has Results
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
7 Completed Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: perifosine;   Drug: dexamethasone
8 Active, not recruiting Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: bortezomib
9 Completed Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: IPI-504
10 Unknown  Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: PRLX 93936
11 Completed
Has Results
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Plitidepsin
12 Active, not recruiting
Has Results
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: dexamethasone
13 Recruiting Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
Condition: Relapsed and/or Relapsed-refractory Multiple Myeloma
Interventions: Drug: Melflufen;   Drug: Dexamethasone
14 Recruiting Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy
Conditions: Acute Leukaemia;   Chronic Leukaemia;   Myeloma;   Lymphoma
Intervention: Radiation: Targeted radiotherapy
15 Recruiting ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
16 Recruiting Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: ACY-241;   Drug: Pomalidomide;   Drug: Dexamethasone
17 Recruiting Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers
Conditions: Graft Versus Host Disease;   Leukemia;   Lymphoma;   Myeloma;   Myelodysplastic Syndrome
Interventions: Other: CD4 DLI;   Other: No DLI

Indicates status has not been verified in more than two years